GLUCOTRACK INC (GCTK)
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
$0.38-5.00%
Close 2026-11-05 · 1-day change
NASDAQHealth CareMedical - DevicesSnapshot 2026-11-04
QuarterlyIQ Insights · GCTK
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 870.8% |
| Our one-year growth estimate | diamond | -29.1% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-11-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 899.9 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of —
GCTK — legal / regulatory event — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standar…
Dated 2026-10-29
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. As previously disclosed, Glucotrack, Inc. (the “Company”) received a determination from The Nasdaq Stock Market LLC (“Nasdaq”) to delist the Company’s securities for failure to comply with the $1.00 minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Rule”). Following a hearing, a Nasdaq Hearings Panel (the “Panel”) granted the Company an exception to regain complia…
Why it matters: Nasdaq set a deadline for GCTK to keep its closing bid at $1 or more. Failure could put its listing at risk.
Worry ifGCTK closes below $1 on any trading day through November 9, 2026, or Nasdaq sends a delisting notice.
Less concerning ifGCTK closes at or above $1 each trading day through November 9, 2026, and Nasdaq confirms the listing exception is still in force.
Why it matters: GCTK reported $3.9 million in cash and $4.1 million used in operations in Q1. New funding may add cash, but also debt or share dilution.
Worry ifThe November 12 report shows cash below $2 million, higher debt, or new share issuance to fund operations.
Less concerning ifThe report shows cash above $3 million, lower debt, and no new share issuance since the latest disclosed financing.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$645 on $10,000 · ±6.5% | How much price usually moves either way. |
| Bad day | $1,991 loss on $10,000 · 19.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $9,978 loss on $10,000 · 99.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.